Pourchet V, Roussel X, Biichlé S, Labaigt T, Roggy A, Fournet T, Zalmaï L, Guignedoux G, Bouyer S, Raimbault A, Courtois L, Brouzes C, Lhermitte L, Hardeman A, Podvin B, Daguindau E, Deconinck E, Garnache-Ottou F, Renosi F

Haematologica. 2026 07 23;:

Contribution of a specific panel by flow cytometry for the differential diagnosis of plasmacytoid dendritic cell neoplasms.

Renosi F, Biichlé S, Roussel X, Fournet T, Roggy A, Pourchet V, Berry JF, Fredon M, Poussard M, Asnafi V, Macintyre E, Preudhomme C, Roumier C, Deconinck E, Daguindau E, Adotévi O, Angelot-Delettre F, Garnache-Ottou F

Ann Hematol. 2026 02 17;105(4):122

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, Ulrickson ML, Schiller GJ, Erba HP, Wang ES, Walter RB, Deconinck E, Aribi A, Legrand O, Lebon D, Maisano V, Martinelli G, DeAngelo DJ, Derenzini E, Du Y, Lakshmikanthan S, Potluri J, Kantarjian HM, Daver NG

J Clin Oncol. 2026 02 11;:JCO2502083

Hematologic Landscape of Adult Patients With Diamond-Blackfan Anemia Syndrome.

Lecornec N, de Fontbrune FS, Forcade E, Garçon L, Terriou L, Cougoul P, Delavigne K, Marie I, Brindel I, Deconinck É, Daguindau É, Amé S, Ledoux MP, Sanhes L, Nimubona S, Leverger G, de Montalembert M, de Latour RP, Dalle JH, Fenaux P, Costa LD, Leblanc T

Am J Hematol. 2026 01 7;:

Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.

Angelucci E, Deconinck E, Benoit TM, Braitsch K, Papayannidis C, Schmaelter AK, Erakli D, Zuurman M, Herling M

Leuk Lymphoma. 2025 09 18;:1-9

Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naïve patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program.

Herling M, Angelucci E, Benoit TM, Rivoli G, Curti A, Götze KS, Wirths S, Erakli D, Zuurman M, Deconinck E

Ann Hematol. 2025 08 2;:

Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AML.

Dachy G, Labopin M, Socié G, Castilla-Llorente C, Forcade E, Blau IW, Ceballos P, Deconinck E, Burns D, Bulabois CE, Vrhovac R, Huynh A, Blaise D, Maertens J, Schroeder T, Bay JO, Savani B, Spyridonidis A, Ciceri F, Mohty M

Bone Marrow Transplant. 2025 06 19;:

Venetoclax-Proteasome inhibitor-Dexamethasone for unfit patients with Blastic Plasmacytoid Dendritic Cell Neoplasm.

Khalife-Hachem S, Pages A, Akoury E, Bonnet S, Birsen R, Busquet C, Contejean A, Danu A, De Botton S, De Charette M, Dumas PY, Jaccard A, Marfaing-Koka A, Willekens C, Deconinck E, Ghez D

Blood Adv. 2024 12 4;:

Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.

Arrieta-Bolaños E, van der Burg LLJ, Gedde-Dahl T, Robin M, Salmenniemi U, Kröger N, Yakoub-Agha I, Huynh A, Crawley C, Deconinck E, Bulabois CE, Forcade E, Tholouli E, van der Hem JGK, van Balen P, Hoogenboom JD, de Wreede LC, Malard F, Ruggeri A, Fleischhauer K

Blood. 2024 10 17;144(16):1747-1751

[Nurturing and growing a community of department heads: Act 2 in haematology].

Houot R, Calmettes C, Park S, Pascal L, Peffault de Latour R, Pigneux A, Quinquenel A, Raffoux E, Thieblemont C, Touati M, Trebouet A, Vaida I, Wémeau M, Bastie JN, Bay JO, Cluzeau T, Cornillon J, Damaj G, Deconinck E, Feugier P, Fornecker LM, Gay J, Hermine O, Hospital MA, Hunault M, Jaccard A, Jardin F, Le Calloch R, Legros L, Leleu X, Lemonnier F, Malfuson JV, Morel P, Ochmann M, Orsini-Piocelle F, Gyan E

Bull Cancer. 2024 09 11;:

Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies.

Arrieta-Bolaños E, Bonneville EF, Crivello P, Robin M, Gedde-Dahl T, Salmenniemi U, Kröger N, Yakoub-Agha I, Crawley C, Choi G, Broers AEC, Forcade E, Carre M, Poiré X, Huynh A, Lenhoff S, Ciceri F, Tholouli E, Schroeder T, Deconinck E, Carlson K, de Wreede LC, Hoogenboom JD, Malard F, Ruggeri A, Fleischhauer K,

J Clin Oncol. 2024 08 21;:JCO2400582

Impact of scFv on functionality and safety of third generation CD123 CAR T cells.

Fredon M, Poussard M, Biichlé S, Bonnefoy F, Mantion CF, Seffar E, Renosi F, Bôle-Richard E, Boidot R, Chevrier S, Anna F, Loustau M, Caumartin J, Gonçalves-Venturelli M, Robinet E, Saas P, Deconinck E, Daguindau E, Roussel X, Godet Y, Adotévi O, Angelot-Delettre F, Galaine J, Garnache-Ottou F

Cancer Immunol Res. 2024 05 31;:

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.

Crochet G, Iacoboni G, Couturier A, Bachy E, Iraola-Truchuelo J, Gastinne T, Cartron G, Fradon T, Lesne B, Kwon M, Gounot R, Martínez-Cibrian N, Castilla-Llorente C, Abrisqueta P, Guerreiro M, Sarkozy C, Aspa-Cilleruelo JM, Camus V, Guidez S, Chauchet A, Deconinck E, Bouabdallah K, Bosch F, Barba P, Morschhauser F, Houot R

Blood. 2024 04 24;:

Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party Euro

Loke J, Labopin M, Craddock C, Socié G, Gedde-Dahl T, Blaise D, Forcade E, Salmenniemi U, Huynh A, Versluis J, Yakoub-Agha I, Labussière-Wallet H, Maertens J, Passweg J, Bulabois CE, Gabellier L, Mielke S, Castilla-Llorente C, Deconinck E, Brissot E, Nagler A, Ciceri F, Mohty M

Cancer. 2024 04 6;:

Kidney Transplantation After Allogeneic Hematopoietic Cell Transplantation.

Ziliotis MJ, Vauchy C, Deconinck E, Berceanu A, Büchler M, Caillard S, Couzi L, Dussol B, Frimat L, Hazzan M, Jaulin JP, Malvezzi P, Peffault de Latour R, Ducloux D, Courivaud C

Kidney Int Rep. 2024 04;9(4):1127-1131

IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation.

Caillet A, Simonet-Boissard M, Forcade E, Robin M, Rubio MT, Couturier MA, Srour M, Maillard N, Devillier R, Huynh A, Bourhis JH, Simand C, Chantepie S, Boisson C, Kroemer M, Deconinck E, Berceanu A

Hemasphere. 2024 03;8(3):e44

Autologous hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Drozd-Sokolowska J, Gras L, Koster L, Martino R, Salas MQ, Salmenniemi U, Zudaire T, Yañez L, Bellido M, Collin M, Kaufmann M, Kozlowski P, Poiré X, Ferra C, Sampol A, Wilson KMO, Cairoli A, Gedde-Dahl T, Deconinck E, Mirabile M, Suarez F, Raj K, Van Gelder M, Yakoub-Agha I, Tournilhac O, McLornan DP

Haematologica. 2024 01 11;:

Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Pemmaraju N, Deconinck E, Mehta P, Walker I, Herling M, Garnache-Ottou F, Gabarin N, Campbell CJV, Duell J, Moshe Y, Mughal T, Mohty M, Angelucci E

Clin Lymphoma Myeloma Leuk. 2023 12 20;:

Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab.

Rodier C, Kanagaratnam L, Morland D, Herbin A, Durand A, Chauchet A, Choquet S, Colin P, Casasnovas RO, Deconinck E, Godard F, Delmer A, Rossi C, Durot E

Hemasphere. 2023 05;7(5):e861

Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.

Gagelmann N, Eikema DJ, Koster L, Netelenbos T, McDonald A, Stoppa AM, Fenk R, Anagnostopoulos A, van Gorkom G, Deconinck E, Bulabois CE, Delforge M, Bunjes D, Arcese W, Reményi P, Itälä-Remes M, Thurner L, Bolaman AZ, Nabil Y, Lund J, Labussière-Wallet H, Hayden PJ, Beksac M, Schönland S, Yakoub-Agha I

Eur J Haematol. 2023 04 21;:

MPN-467 Findings From an Observational, Multicenter, Retrospective Analysis of Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With Tagraxofusp in the European Expanded Access Program.

Herling M, Deconinck E, Anant M, Manteigas D, Riggi M, Mughal T, Angelucci E

Clin Lymphoma Myeloma Leuk. 2022 10;22 Suppl 2:S338

Acute fulminant hepatitis related to the use of dasatinib: first case report.

Clément M, Cervoni JP, Renosi F, Thévenot T, Felix S, Doussot A, Heyd B, Deconinck É, Martino VD

Clin Res Hepatol Gastroenterol. 2022 08 9;:102004

Conventional Therapeutics in BPDCN Patients-Do They Still Have a Place in the Era of Targeted Therapies?

Poussard M, Angelot-Delettre F, Deconinck E

Cancers (Basel). 2022 08 2;14(15):

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.

Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, Haderbache R, Roussel X, Desbrosses Y, Daguindau E, Renosi F, Roumier C, Bouquet L, Biichle S, Guiot M, Seffar E, Caillot D, Depil S, Robinet E, Salma Y, Deconinck E, Deschamps M, Ferrand C

J Immunother Cancer. 2022 07;10(7):

Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation.

Ruggeri A, De Wreede LC, Müller CR, Crivello P, Bonneville EF, Petersdorf EW, Socié G, Dubois V, Niittyvuopio R, Peräsaari J, Yakoub-Agha I, Cornelissen JJ, Wieten L, Gedde-Dahl T, Forcade E, Crawley CR, Marsh SGE, Gandemer V, Tholouli E, Bulabois CE, Huynh A, Choi G, Deconinck E, Itäla-Remes M, Lenhoff S, Bengtsson M, Johansson JE, Van Gorkom G, Hoogenboom JD, Vago L, Rocha V, Bonini C, Chabannon C, Fleischhauer K

Haematologica. 2022 05 12;:

An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2 myeloproliferative neoplasms.

Moraes GR, Pasquier F, Marzac C, Deconinck E, Damanti CC, Leroy G, El-Khoury M, El Nemer W, Kiladjian JJ, Raslova H, Najman A, Vainchenker W, Marty C, Bellanné-Chantelot C, Plo I

Br J Haematol. 2022 Mar 30;:

Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP.

Onida F, Sbianchi G, Radujkovic A, Sockel K, Kröger N, Sierra J, Socié G, Cornelissen J, Poiré X, Raida L, Bourhis JH, Finke J, Passweg J, Salmenniemi U, Schouten HC, Beguin Y, Martin S, Deconinck E, Ganser A, Zver S, Lioure B, Rohini R, Koster L, Hayden P, Iacobelli S, Robin M, Yakoub-Agha I

Bone Marrow Transplant. 2022 Mar 29;:

Vaccination coverage in hematological patients undergoing chemotherapy: Should we move towards personalized vaccination?

Pierron A, Bozon F, Berceanu A, Fontan J, Brion A, Deconinck E, Chirouze C, Brunel AS

Vaccine. 2021 Nov 2;:

Lymphoblastic T Cells and Mature NK Cells With the Same TCRγ Rearrangement: A Common Origin?

Roggy A, Biichle S, Ferrand C, Renosi F, Larosa F, Deconinck E, Daguindeau E, Collonge Rame MA, Schillinger F, Seilles E, Garnache-Ottou F

Hemasphere. 2021 Aug;5(8):e608

Oral therapy adherence and satisfaction in patients with multiple myeloma.

Solano M, Daguindau E, Faure C, Loriod P, Pain C, Maes AC, Marguet P, Kroemer M, Rumpler A, Fontan J, Deconinck E, Limat S, Clairet AL

Ann Hematol. 2021 May 3;:

Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.

Kharfan-Dabaja MA, Labopin M, Brissot E, Kroger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, Ganser A, Stelljes M, Edinger M, Savani B, Ruggeri A, Sanz J, Nagler A, Mohty M

Br J Haematol. 2021 Apr 10;:

Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis.

Renosi F, Roggy A, Giguelay A, Soret L, Viailly PJ, Cheok M, Biichle S, Angelot-Delettre F, Asnafi V, Macintyre E, Geffroy S, Callanan M, Petrella T, Deconinck E, Daguindau E, Harrivel V, Bouyer S, Salaun V, Saussoy P, Feuillard J, Fuseau P, Saas P, Adotévi O, Jardin F, Ferrand C, Preudhomme C, Colinge J, Roumier C, Garnache-Ottou F

Blood Adv. 2021 Mar 9;5(5):1540-1551

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR-T cell cytotoxicity.

Poussard M, Philippe L, Fredon M, Bôle-Richard E, Biichle S, Renosi F, Perrin S, Kroemer M, Limat S, Bonnefoy F, Daguindau E, Deconinck E, Gruson B, Saas P, Adotévi O, Garnache-Ottou F, Angelot-Delettre F

EJHaem. 2021 02;2(1):125-130

Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP-EBMT.

Cesaro S, Tridello G, Knelange NS, Blijlevens N, Martin M, Snowden JA, Malladi R, Ljungman P, Deconinck E, Gedde-Dahl T, Byrne J, Xhaard A, Chevallier P, Maertens J, Zuckerman T, Lioure B, Petersen E, Cornelissen JJ, Arcese W, Blaise D, Milpied N, Cahn JY, Aljurf M, de Wreede L, Mauro M, de la Camara R, Averbuch D, Mikulska M, Styczynski J

Bone Marrow Transplant. 2021 Jan 29;:

Investigating the impact of posaconazole prophylaxis on systematic fungal screening using galactomannan antigen, Aspergillus fumigatus qPCR, and Mucorales qPCR.

Bellanger AP, Tatoyan N, Monnot T, Deconinck E, Scherer E, Montange D, Bichard D, Millon L, Gbaguidi-Haore H, Berceanu A

J Mycol Med. 2021 Jan 28;31(2):101117

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.

Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, Maloisel F, Rea D, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Jourdan E, Berger M, Fouillard L, Alexis M, Legros L, Rousselot P, Delmer A, Lenain P, Escoffre Barbe M, Gyan E, Bulabois CE, Dubruille V, Joly B, Pollet B, Cony-Makhoul P, Johnson-Ansah H, Mercier M, Caillot D, Charbonnier A, Kiladjian JJ, Chapiro J, Penot A, Dorvaux V, Vaida I, Santagostino A, Roy L, Zerazhi H, Deconinck E, Maisonneuve H, Plantier I, Lebon D, Arkam Y, Cambier N, Ghomari K, Miclea JM, Glaisner S, Cayuela JM, Chomel JC, Muller M, Lhermitte L, Delord M, Preudhomme C, Etienne G, Mahon FX, Nicolini FE,

Leukemia. 2021 Jan 22;:

A case report of blastic plasmacytoid dendritic cell neoplasm in a hispanic child.

Tanchiva KO, Chavez PC, Guevara SLL, Vicuña CRQ, Bhardwaj N, Lansigan F, Deconinck E

Leuk Res Rep. 2021 ;16:100262

Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases.

Fatobene G, Volt F, Moreira F, Mariano L, Chevallier P, Furst S, Labussière-Wallet H, de la Tour RP, Deconinck E, Cluzeau T, Russell N, Karakasis D, Forcade E, Ruggeri A, Gluckman E, Rocha V

Blood Adv. 2020 Dec 22;4(24):6327-6335

Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study.

Beauvais D, Drumez E, Blaise D, Peffault de Latour R, Forcade E, Ceballos P, Uyttebroeck A, Labussière H, Nguyen S, Bourhis JH, Chevallier P, Thiebaut A, Poiré X, Maury S, Deconinck E, Cluzeau T, Brissot E, Huynh A, Rubio MT, Duhamel A, Yakoub-Agha I

Bone Marrow Transplant. 2020 Dec 18;:

Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT.

Paviglianiti A, Labopin M, Blaise D, Socié G, Bulabois CE, Lioure B, Ceballos P, Blau IW, Guillerm G, Maertens J, Chevallier P, Huynh A, Turlure P, Deconinck E, Forcade E, Nagler A, Mohty M

Bone Marrow Transplant. 2020 Nov 28;:

Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide.

Chevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert BM, Daguindau E, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Tessoulin B, Vantyghem S, Desbrosses Y, Bressollette C, Duquesne A, Eveillard M, Le Bris Y, Dormoy A, Malugani C, Deconinck E, Moreau P, Le Gouill S, Béné MC, Guillaume T

Acta Oncol. 2020 Oct 28;:1-9

Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape.

Zalmaï L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F, Petrella T, Collonge-Rame MA, Seilles E, Geffroy S, Deconinck E, Daguindau E, Bouyer S, Dindinaud E, Baunin V, Le Garff-Tavernier M, Roos-Weil D, Wagner-Ballon O, Salaun V, Feuillard J, Brun S, Drenou B, Mayeur-Rousse C, Okamba P, Dorvaux V, Tichionni M, Rose J, Rubio MT, Jacob MC, Raggueneau V, Preudhomme C, Saas P, Ferrand C, Adotevi O, Roumier C, Jardin F, Garnache-Ottou F, Renosi F

Haematologica. 2020 Oct 13;Online ahead of print:

Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT.

Bento L, Boumendil A, Finel H, Khvedelidze I, Blaise D, Fegueux N, Castagna L, Forcade E, Chevallier P, Mordini N, Brice P, Deconinck E, Gramatzki M, Corradini P, Hunault M, Musso M, Tsoulkani A, Caballero D, Nati S, Montoto S, Sureda A,

Bone Marrow Transplant. 2020 Oct 12;:

Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.

Schetelig J, Chevallier P, van Gelder M, Hoek J, Hermine O, Chakraverty R, Browne P, Milpied N, Malagola M, Socié G, Delgado J, Deconinck E, Damaj G, Maury S, Beelen D, Quoc SN, Shankara P, Brecht A, Mayer J, Hunault-Berger M, Bittenbring J, Thieblemont C, Lepretre S, Baldauf H, de Wreede LC, Tournilhac O, Yakoub-Agha I, Kröger N, Dreger P

. 2020 Oct 2;:

Pyogenic Granuloma During Ibrutinib Therapy for B-Cell Neoplasia.

Roussel X, Charollais R, Deconinck E, Daguindau E, Brion A

JCO Oncol Pract. 2020 Aug 17;:OP2000037

Platelet transfusions in haematologic malignancies in the last six months of life.

Moracchini J, Seigeot A, Angelot-Delettre F, Vienot A, Aubry R, Daguindau É, Deconinck E, Frache S, Tiberghien P

Vox Sang.. 2020 Aug 13;:

Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.

Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, Rovira M, Ciceri F, Griskevicius L, Blaise D, Forcade E, Mistrik M, Mielke S, Bulabois CE, Niittyvuopio R, Deconinck E, Ruggeri A, Sanz J, Spyridonidis A, Savani B, Giebel S, Nagler A, Mohty M

J Hematol Oncol. 2020 Jul 3;13(1):87

Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia.

Rogier T, Samson M, Mourey G, Falvo N, Magy-Bertrand N, Ouandji S, Picque JB, Greigert H, Mausservey C, Imbach A, Ghesquière T, Voillat L, Caillot D, Deconinck E, Bonnotte B, Audia S

J Clin Med. 2020 Jun 25;9(6):

Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: on behalf of the ALWP/EBMT.

Nagler A, Labopin M, Canaani J, Niittyvuopio R, Socié G, Kröger N, Itäla-Remes M, Yakoub-Agha I, Labussière-Wallet H, Gallego-Hernanz MP, Deconinck E, Chevallier P, Finke J, Esteve J, Mohty M

Am. J. Hematol.. 2020 Jun 12;:

Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Presentation and Diagnosis.

Deconinck E, Petrella T, Garnache Ottou F

Hematol. Oncol. Clin. North Am.. 2020 Jun;34(3):491-500

Blastic Plasmacytoid Dendritic Cell Neoplasm: The European Perspective.

Deconinck E

Hematol. Oncol. Clin. North Am.. 2020 Jun;34(3):613-620

Impact of detectable measurable residual disease on umbilical cord blood transplantation.

Baron F, Labopin M, Ruggeri A, Sierra J, Robinson S, Labussière-Wallet H, Potter M, Ribera JM, Deconinck E, Rambaldi A, Rohrlich PS, de Revel T, Gluckman E, Nagler A, Mohty M

Am. J. Hematol.. 2020 May 25;:

Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma.

Van de Wyngaert Z, Nerich V, Fouquet G, Chrétien ML, Caillot D, Azar N, Garderet L, Lenain P, Macro M, Bourhis JH, Belhocine R, Jaccard A, Karlin L, Bobin A, Moya N, Systchenko T, Gruchet C, Giraud C, Guidez S, Darras C, Princet I, Touzeau C, Moreau P, Hulin C, Deconinck E, Limat S, Leleu X,

Bone Marrow Transplant.. 2020 May 23;:

CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the European

Maffini E, Labopin M, Blaise D, Ciceri F, Gülbas Z, Deconinck E, Leblond V, Chevallier P, Sociè G, Araujo MC, Koc Y, Savani BN, Gorin NC, Lanza F, Nagler A, Mohty M

Am. J. Hematol.. 2020 Apr 17;:

CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.

Bôle-Richard E, Fredon M, Biichlé S, Anna F, Certoux JM, Renosi F, Tsé F, Molimard C, Valmary-Degano S, Jenvrin A, Warda W, Pallandre JR, Bonnefoy F, Poussard M, Deschamps M, Petrella T, Roumier C, Macintyre E, Féger F, Brissot E, Mohty M, HoWangYin KY, Langlade-Demoyen P, Loustau M, Caumartin J, Godet Y, Binda D, Pagadoy M, Deconinck E, Daguindau E, Saas P, Ferrand C, Angelot-Delettre F, Adotévi O, Garnache-Ottou F

Leukemia. 2020 Feb 28;:

Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.

Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Warda W, Neto da Rocha M, Trad R, Deconinck E, Deschamps M, Ferrand C

Front Oncol. 2020 ;10:599933

Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old Woman.

Cochet C, Simonet M, Cattin J, Metz JP, Berceanu A, Deconinck E, Daguindau E, Schillinger F, Fenaux P, Mottet N, Desbrosses Y

Case Rep Hematol. 2020 ;2020:3686584

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E, Soret L, Schillinger F, Puyraimond S, Petrella T, Preudhomme C, Roumier C, MacIntyre EA, Harrivel V, Desbrosses Y, Gruson B, Geneviève F, Thepot S, Drebit Y, Leguay T, Gros FX, Lechevalier N, Saussoy P, Salaun V, Cornet E, Benseddik Z, Veyrat-Masson R, Wagner-Ballon O, Salanoubat C, Maynadié M, Guy J, Caillot D, Jacob MC, Cahn JY, Gressin R, Rose J, Quesnel B, Guerin E, Trimoreau F, Feuillard J, Gourin MP, Plesa A, Baseggio L, Arnoux I, Vey N, Blaise D, Lacroix R, Arnoulet C, Benet B, Dorvaux V, Bret C, Drenou B, Debliquis A, Latger-Cannard V, Bonmati C, Bene MC, Peterlin P, Ticchioni M, Rohrlich PS, Arnaud A, Wickenhauser S, Bardet V, Brechignac S, Papoular B, Raggueneau V, Vargaftig J, Letestu R, Lusina D, Braun T, Foissaud V, Tamburini J, Bennani H, Freynet N, Cordonnier C, Le Garff-Tavernier M, Jacques N, Maloum K, Roos-Weil D, Bouscary D, Asnafi V, Lhermitte L, Suarez F, Lengline E, Féger F, Battipaglia G, Mohty M, Bouyer S, Ghoual O, Dindinaud E, Basle C, Puyade M, Lafon C, Fest T, Roussel M, Cahu X, Bera E, Daliphard S, Jardin F, Campos L, Solly F, Guyotat D, Galoisy AC, Eischen A, Mayeur-Rousse C, Guffroy B, Recher C, Loosveld M, Garnier A, Barlogis V, Rosenthal MA, Brun S, Contentin N, Maury S, Callanan M, Lefebvre C, Maillard N, Okamba P, Ferrand C, Adotevi O, Saas P, Angelot-Delettre F, Binda D, Deconinck E

Blood Adv. 2019 Dec 23;3(24):4238-4251

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT.

Shimoni A, Labopin M, Finke J, Ciceri F, Deconinck E, Kröger N, Gramatzki M, Stelljes M, Blaise D, Stoelzel F, Chevallier P, Holler E, Fegueux N, Mohty M, Nagler A

Blood Cancer J. 2019 Nov 18;9(12):88

The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.

Nagler A, Dholaria B, Labopin M, Socie G, Huynh A, Itälä-Remes M, Deconinck E, Yakoub-Agha I, Cahn JY, Bourhis JH, Labussière-Wallet H, Chantepie S, Esteve J, Savani B, Mohty M

Leukemia. 2019 Nov 14;:

Correction of Severe Myelofibrosis, Impaired Platelet Functions and Abnormalities in a Patient with Gray Platelet Syndrome Successfully Treated by Stem Cell Transplantation.

Favier R, Roussel X, Audia S, Bordet JC, De Maistre E, Hirsch P, Neuhart A, Bedgedjian I, Gkalea V, Favier M, Daguindau E, Nurden P, Deconinck E

Platelets. 2019 Sep 10;:1-5

Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT.

Styczynski J, Tridello G, Gil L, Ljungman P, Mikulska M, Ward KN, Cordonnier C, de la Camara R, Averbuch D, Knelange N, Socié G, Chevallier P, Blaise D, Yakoub-Agha I, Forcade E, Cornelissen J, Maertens J, Petersen E, Nguyen-Quoc S, Veelken H, Schaap N, Passweg J, Michallet M, Fegueux N, Deconinck E, Russell N, Basak G, Bader P, Montoto S, Kröger N, Cesaro S,

Bone Marrow Transplant.. 2019 Jul 30;:

Altered thymic CD4 T-cell recovery after allogeneic hematopoietic stem cell transplantation is critical for nocardiosis.

Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Saas P, Ferrand C, Seilles E, Pouthier F, Deconinck E, Larosa F

Curr Res Transl Med. 2019 Jun 1;:

Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT.

Ruggeri A, Labopin M, Savani B, Paviglianiti A, Blaise D, Volt F, Ciceri F, Bacigalupo A, Tischer J, Chevallier P, Koc Y, Cornelissen JJ, Ehninger G, Sanz G, Deconinck E, Rocha V, Baron F, Mohty M, Gluckman E, Nagler A

Bone Marrow Transplant.. 2019 May 31;:

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).

Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ, Hoek J, Potter M, Wulf G, Sellner L, Ljungman P, Chevallier P, Volin L, Koc Y, Martin S, Bunjes D, Rovira M, Itälä-Remes M, Foá R, Deconinck E, Gedde-Dahl T, Cornelissen J, Collin M, Brecht A, Patel A, de Groot M, Reményi P, Nagler A, Finke J, Turlure P, Iacobelli S, van Biezen A, Schetelig J, Kröger N, Dreger P

Bone Marrow Transplant.. 2019 Jan 21;:

Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos-channelopathy: A retrospective series of 126 patients.

Picard V, Guitton C, Thuret I, Rose C, Bendelac L, Ghazal K, Aguilar-Martinez P, Badens C, Barro C, Bénéteau C, Berger C, Cathébras P, Deconinck E, Delaunay J, Durand JM, Firah N, Galactéros F, Godeau B, Jaïs X, de Jaureguiberry JP, Le Stradic C, Lifermann F, Maffre R, Morin G, Perrin J, Proulle V, Ruivard M, Toutain F, Lahary A, Garçon L

Haematologica. 2019 Jan 17;:

CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells.

Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z, Faure C, Caillot D, Moldovan M, Valmary-Degano S, Biichle S, Daguindau E, Garnache-Ottou F, Tabruyn S, Adotévi O, Deschamps M, Ferrand C

Cancer Res.. 2018 Dec 4;:

Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission.

Poiré X, Labopin M, Polge E, Blaise D, Chevallier P, Maertens J, Deconinck E, Forcade E, Rambaldi A, Baerlocher GM, Zuckerman T, Volin L, Schouten HC, Ifrah N, Mohty M, Esteve J, Nagler A

Am. J. Hematol.. 2018 Nov 19;:

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

Adès L, Thomas X, Guerci Bresler A, Raffoux E, Spertini O, Vey N, Marchand T, Récher C, Pigneux A, Girault S, Deconinck E, Gardin C, Tournilhac O, Lambert JF, Chevallier P, de Botton S, Lejeune J, Dombret H, Chevret S, Fenaux P,

Haematologica. 2018 Jul 19;:

Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu

Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socié G, Ljungman P, Huynh A, Deconinck E, Wu D, Bourhis JH, Cahn JY, Polge E, Mohty M, Savani BN, Nagler A

Am. J. Hematol.. 2018 Jul 7;:

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leuk

Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, Blaise D, Arcese W, Socié G, Bourhis JH, Van Lint M, Bruno B, Huynh A, Santarone S, Deconinck E, Mohty M, Nagler A

Haematologica. 2018 May 10;:

A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN analyzers in routine laboratory practice.

Schillinger F, Sourdeau E, Boubaya M, Baseggio L, Clauser S, Cornet E, Debord C, Defour JP, Dubois F, Eveillard M, Galoisy AC, Geay MO, Mullier F, Nivaggioni V, Soenen V, Morel P, Garnache-Ottou F, Ronez E, Bardet V, Deconinck E

Scand. J. Clin. Lab. Invest.. 2018 05;78(3):159-164

Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia.

Peffault de Latour R, Tabrizi R, Marcais A, Leblanc T, Lamy T, Mohty M, Tavitian S, Jubert C, Pasquet M, Galambrun C, Nguyen S, Cahn JY, Braun T, Deconinck E, Bay JO, Sicre de Fontbrune F, Barraco F, Socié G

Am. J. Hematol.. 2018 May;93(5):635-642

Development of a quantitative PCR detecting Cunninghamella bertholletiae to help in diagnosing this rare and aggressive mucormycosis.

Bellanger AP, Berceanu A, Rocchi S, Valot B, Fontan J, Chauchet A, Belin N, Scherer E, Deconinck E, Navellou JC, Millon L

Bone Marrow Transplant.. 2018 Apr 30;:

Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.

Garban F, Guyard A, Labussière H, Bulabois CE, Marchand T, Mounier C, Caillot D, Bay JO, Coiteux V, Schmidt-Tanguy A, Le Niger C, Robin C, Ladaique P, Lapusan S, Deconinck E, Rolland C, Foote AM, François A, Jacquot C, Tardivel R, Tiberghien P, Bosson JL,

JAMA Oncol. 2018 Apr 1;4(4):468-475

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A,

J. Intern. Med.. 2018 Apr;283(4):371-379

Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.

Shimoni A, Labopin M, Savani B, Hamladji RM, Beelen D, Mufti G, Socié G, Delage J, Blaise D, Chevallier P, Forcade E, Deconinck E, Mohty M, Nagler A

Biol. Blood Marrow Transplant.. 2018 Apr;24(4):751-757

Factors related to the outcome of prophylactic platelet transfusions in patients with hematologic malignancies: an observational study.

Seigeot A, Desmarets M, Rumpler A, Leroux F, Deconinck E, Monnet E, Bardiaux L

Transfusion. 2018 Mar 14;:

Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy,

Tozatto-Maio K, Giannotti F, Labopin M, Ruggeri A, Volt F, Paviglianiti A, Kenzey C, Hayashi H, Cornelissen J, Michallet M, Karakasis D, Deconinck E, Rohrlich PS, de la Tour RP, Blaise D, Petersen E, D'Aveni M, Sengeloev H, Lamy T, Russell NH, Forcade E, Craddock CF, Nagler A, Gluckman E, Rocha V

Biol. Blood Marrow Transplant.. 2018 Mar 1;:

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellula

Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, Beckerich F, Suarez F, Chevallier P, Nguyen-Quoc S, Ledoux MP, Clement L, Hicheri Y, Guillerm G, Cornillon J, Contentin N, Carre M, Maillard N, Mercier M, Mohty M, Beguin Y, Bourhis JH, Charbonnier A, Dauriac C, Bay JO, Blaise D, Deconinck E, Jubert C, Raus N, Peffault de Latour R, Dhedin N

Am. J. Hematol.. 2018 Mar;93(3):416-423

Incidence, Risk Factors and Long-Term Outcome of Acute Leukemia Patients with Early Candidemia after Allogeneic Stem Cell Transplantation. A Study by the Acute Leukemia and Infectious Diseases Working Parties of EBMT.

Cesaro S, Tridello G, Blijlevens N, Ljungman P, Craddock C, Michallet M, Martin A, Snowden JA, Mohty M, Maertens J, Passweg J, Petersen E, Nihtinen A, Isaksson C, Milpied N, Rohlich PS, Deconinck E, Crawley C, Ledoux MP, Hoek J, Nagler A, Styczynski J

Clin. Infect. Dis.. 2018 Feb 22;:

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.

Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury J, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Tournilhac O, Branger B, Devillers A, Vuillez JP, Fest T, Colombat P, Costes V, Szablewski V, Béné MC, Delwail V,

Blood. 2018 Jan 11;131(2):174-181

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.

Saraceni F, Labopin M, Hamladji RM, Mufti G, Socié G, Shimoni A, Delage J, Deconinck E, Chevallier P, Blaise D, Sanz J, Huynh A, Forcade E, Savani BN, Mohty M, Nagler A,

Oncotarget. 2018 Jan 9;9(3):3379-3393

More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.

Tiberghien P, Deconinck E, Adotevi O

N. Engl. J. Med.. 2017 11 23;377(21):2101-2

Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cel

Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois CE, Bay JO, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich PS, N'Guyen S, Maillard N, Marchand T, Mohty M, Chevallier P,

Ann. Oncol.. 2017 Sep;28(9):2191-2198

Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.

Philippe L, Ceroi A, Bôle-Richard E, Jenvrin A, Biichle S, Perrin S, Limat S, Bonnefoy F, Deconinck E, Saas P, Garnache-Ottou F, Angelot-Delettre F

Haematologica. 2017 Aug;:

Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT.

Canaani J, Beohou E, Labopin M, Socié G, Huynh A, Volin L, Cornelissen J, Milpied N, Gedde-Dahl T, Deconinck E, Fegueux N, Blaise D, Mohty M, Nagler A

Am. J. Hematol.. 2017 Apr;92(4):344-350

Paecilomyces variotii Fungemia in a Patient with Lymphoma Needing Liver Transplant.

Bellanger AP, Cervoni JP, Faucher JF, Weil-Verhoeven D, Ginet M, Deconinck E, Grenouillet F

Mycopathologia. 2017 Apr;:

DNA damage response defect in Williams-Beuren syndrome.

Guenat D, Merla G, Deconinck E, Borg C, Rohrlich PS

Int. J. Mol. Med.. 2017 Mar;39(3):622-628

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

Wang L, Raffoux E, Thomas X, Yakoub-Agha I, Bouhris JH, de Botton S, Michallet M, Quoc SN, Chantepie S, Deconinck E, Caillot D, Turlure P, Vigouroux S, Pigneux A, Huynh A, Malfuson JV, Loschi M, Socie G, Dombret H, de la Tour RP, Cluzeau T

Leuk. Res.. 2017 Mar;54:12-16

Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the EBMT.

Canaani J, Labopin M, Socié G, Nihtinen A, Huynh A, Cornelissen J, Deconinck E, Gedde-Dahl T, Forcade E, Chevallier P, Bourhis JH, Blaise D, Mohty M, Nagler A

Am. J. Hematol.. 2017 Mar;:

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1.

Versluis J, Labopin M, Ruggeri A, Socie G, Wu D, Volin L, Blaise D, Milpied N, Craddock C, Yakoub-Agha I, Maertens J, Ljungman P, Huynh A, Michallet M, Deconinck E, Chevallier P, Passweg J, Ciceri F, Mohty M, Cornelissen JJ, Nagler A

Blood Adv. 2017 Feb 28;1(7):477-485

DNA damage response defect in Williams-Beuren syndrome.

Guenat D, Merla G, Deconinck E, Borg C, Rohrlich PS

Int. J. Mol. Med.. 2017 Jan;:

Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.

Paviglianiti A, Xavier E, Ruggeri A, Ceballos P, Deconinck E, Cornelissen JJ, Nguyen-Quoc S, Maillard N, Sanz G, Rohrlich PS, Garderet L, Volt F, Rocha V, Kroeger N, Gluckman E, Fegueux N, Mohty M

Haematologica. 2016 Sep;101(9):1120-7

Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.

Bôle-Richard E, Gamonet C, Certoux JM, Idirene I, Larosa F, Deconinck E, Mosseley AM, Tiberghien P, Borg C, Ferrand C, Deschamps M

Gene Ther.. 2016 Aug;23(8-9):664-72

Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.

Philippe L, Helias P, Puyraveau M, Boulahdour H, Deconinck E, Daguindau E

Bone Marrow Transplant.. 2016 Aug;51(8):1140-2

Is shared decision-making vanishing at the end-of-life? A descriptive and qualitative study of advanced cancer patients' involvement in specific therapies decision-making.

Beaussant Y, Mathieu-Nicot F, Pazart L, Tournigand C, Daneault S, Cretin E, Godard-Marceau A, Chassagne A, Trimaille H, Bouleuc C, Cuynet P, Deconinck E, Aubry R

BMC Palliat Care. 2015 Nov;14:61

A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.

Hunault-Berger M, Leguay T, Huguet F, Lepretre S, Deconinck E, Ojeda-Uribe M, Bonmati C, Escoffre-Barbe M, Bories P, Himberlin C, Chevallier P, Rousselot P, Reman O, Boulland ML, Lissandre S, Turlure P, Bouscary D, Sanhes L, Legrand O, Lafage-Pochitaloff M, Bene MC, Liens D, Godfrin Y, Ifrah N, Dombret H

Am J Hematol. 2015 Sep;90(9):811-8

Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy.

Chantepie SP, Michallet M, Blaise D, Maury S, Deconinck E, Tabrizi R, Contentin N, Mohty M, Nguyen S, Lioure B, Raus N, Peffault de Latour R, Yakoub-Agha I, Reman O

Bone Marrow Transplant. 2015 Sep 14

Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Beaussant Y, Daguindau E, Pugin A, Mohty M, Avet-Loiseau H, Roos-Weil D, Michallet M, Chevalier P, Raus N, El-Cheikh J, Tabrizi R, Huyn A, Buzyn A, Socié G, Vincent L, Guilhot F, Yakoub-Agha I, Lenain P, François S, Beckerich F, Lioure B, Bulabois CE, Deconinck E,

Biol. Blood Marrow Transplant.. 2015 Aug;21(8):1452-9

Combining Aspergillus mitochondrial and ribosomal QPCR, in addition to galactomannan assay, for early diagnosis of invasive aspergillosis in hematology patients.

Bellanger AP, Millon L, Berceanu A, Grenouillet F, Grenouillet FE, Larosa F, Deconinck E

Med Mycol. 2015 Jul 10. pii: myv051.

Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of

Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen JJ, Andersen NS, Maillard N, Nguyen S, Blaise D, Deconinck E, Veelken H, Milpied N, Van Gelder M, Peffault de Latour R, Gluckman E, Kroger N, Schetelig J, Rocha V

Biol Blood Marrow Transplant. 2015 May 7. pii: S1083-8791(15)00322-5

Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, Deconinck E, Nagler A, Mohty M

Cancer. 2015 Apr;121(7):1048-55

[Mucositis after allogeneic stem cell transplantation: Risk factors, clinical consequences and prophylaxis].

Bourdelin M, Daguindau E, Larosa F, Legrand F, Nerich V, Deconinck E, Limat S

Pathol. Biol.. 2015 Apr;63(2):106-10

Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC).

Guillaume T, Beguin Y, Tabrizi R, Nguyen S, Blaise D, Deconinck E, Redjoul R, Cornillon J, Guillerm G, Contentin N, Sirvent A, Turlure P, Salmon A, Huynh A, Francois S, Peffault de Latour R, Yakoub-Agha I, Mohty M

Eur J Haematol. 2015 Mar;94(3):265-9

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, Royer B, Deconinck E, Rowinsky EK, Brooks C, Bardet V, Benet B, Bennani H, Benseddik Z, Debliquis A, Lusina D, Roussel M, Solly F, Ticchioni M, Saas P, Garnache-Ottou F

Haematologica. 2015 Feb;100(2):223-30

New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.

Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C

Exp Hematol Oncol. 2015 ;5:7

Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients.

Rahme R, Thomas X, Recher C, Vey N, Delaunay J, Deconinck E, Hirsch P, Bordessoule D, Micol JB, Stamatoullas A, Mariette C, Pautas C, Bories P, Marolleau JP, Hunault-Berger M, Fegueux N, Raffoux E, Dombret H, Degos L, Fenaux P, Ades L

Leukemia. 2014 Dec;28(12):2422-4

Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis.

Robin M, Giannotti F, Deconinck E, Mohty M, Michallet M, Sanz G, Chevallier P, Cahn JY, Legrand F, Rovira M, Passweg J, Sierra J, Nguyen S, Maillard N, Yakoub-Agha I, Linkesch W, Cannell P, Marcatti M, Bay JO, Chalandon Y, Kroger N, Gluckman E, Rocha V, Olavarria E, Ruggeri A

Biol Blood Marrow Transplant. 2014 Nov;20(11):1841-6

Fatal Thrombotic Thrombocytopenic Purpura in a Psoriasis Patient Treated with Ustekinumab and Methotrexate.

Philippe L, Badie J, Faller JP, Kattinger E, Deconinck E, Aubin F

Acta Derm Venereol. 2014 Oct 17

Increased incidence and characteristics of alveolar echinococcosis in patients with immunosuppression-associated conditions.

Chauchet A, Grenouillet F, Knapp J, Richou C, Delabrousse E, Dentan C, Millon L, Di Martino V, Contreras R, Deconinck E, Blagosklonov O, Vuitton DA, Bresson-Hadni S,

Clin. Infect. Dis.. 2014 Oct;59(8):1095-104

Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice.

Bourdelin M, Grenouillet F, Daguindau E, Muret P, Desbrosses Y, Dubut J, Deconinck E, Limat S, Larosa F

Med. Mycol.. 2014 Oct;52(7):728-35

Comparison of umbilical cord blood allogeneic stem-cell transplantation (SCT) vs auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.

Chevallier P, Labopin M, Socie G, Rubio MT, Blaise D, Vigouroux S, Huynh A, Michallet M, Bay JO, Maury S, Yakoub-Agha I, Fegueux N, Deconinck E, Contentin N, Maillard N, Bulabois CE, Francois S, Oumedaly R, Raus N, Mohty M

Eur J Haematol. 2014 Sep 19

Diagnosis and management of nocardiosis after bone marrow stem cell transplantation in adults: lack of lymphocyte recovery as a major contributing factor.

Mansi L, Daguindau E, Saas P, Pouthier F, Ferrand C, Dormoy A, Patry I, Garnache F, Rohrlich PS, Deconinck E, Larosa F

Pathol Biol (Paris). 2014 Jun;62(3):156-61

A 10-year survey of fungal aerocontamination in hospital corridors: a reliable sentinel to predict fungal exposure risk?

Reboux G, Gbaguidi-Haore H, Bellanger AP, Demonmerot F, Houdrouge K, Deconinck E, Bertrand X, Millon L

J Hosp Infect. 2014 May;87(1):34-40

Azole-resistant Aspergillus fumigatus isolate with the TR34/L98H mutation in both a fungicide-sprayed field and the lung of a hematopoietic stem cell transplant recipient with invasive aspergillosis.

Rocchi S, Daguindau E, Grenouillet F, Deconinck E, Bellanger AP, Garcia-Hermoso D, Bretagne S, Reboux G, Millon L

J Clin Microbiol. 2014 May;52(5):1724-6

Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma.

Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S, Woronoff-Lemsi MC, Deconinck E

J Clin Pharm Ther. 2014 Apr;39(2):168-74

Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France.

Labopin M, Ruggeri A, Gorin NC, Gluckman E, Blaise D, Mannone L, Milpied N, Yakoub-Agha I, Deconinck E, Michallet M, Fegueux N, Socie G, Nguyen S, Cahn JY, de Revel T, Garnier F, Faucher C, Taright N, Kenzey C, Volt F, Bertrand D, Mohty M, Rocha V

Haematologica. 2014 Mar;99(3):535-40

Evaluation of invasive aspergillosis risk for immunocompromised patients alternatively hospitalized in hematology intensive care unit and at home.

Rocchi S, Reboux G, Larosa F, Scherer E, Daguindau E, Berceanu A, Deconinck E, Millon L, Bellanger AP

Indoor Air. 2014 Mar 13

Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry.

Wallet HL, Sobh M, Morisset S, Robin M, Fegueux N, Furst S, Mohty M, Deconinck E, Fouillard L, Bordigoni P, Rio B, Sirvent A, Renaud M, Dhedin N, Tabrizi R, Maury S, Buzyn A, Michel G, Maillard N, Cahn JY, Bay JO, Yakoub-Agha I, Huynh A, Schmidt-Tanguy A, Lamy T, Lioure B, Raus N, Marry E, Garnier F, Balere ML, Gluckman E, Rocha V, Socie G, Blaise D, Milpied N, Michallet M

Exp Hematol. 2013 Nov;41(11):924-33

Opposing Mcl-1, the GALIG proapoptotic gene is upregulated as neutrophils die and underexpressed in Acute Myeloid Leukemia cells.

Mollet L, Robinet P, Dubois M, Aurouet A, Normand T, Charpentier S, Sureau A, Grandclement C, Garnache-Ottou F, Deconinck E, Brule F, Rohrlich PS, Legrand A

Mol Immunol. 2013 Nov;56(1-2):123-8

Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita.

Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M, Bodhi P, Davis J, Davies SM, Deconinck E, Deeg HJ, Duerst RE, Fasth A, Ghavamzadeh A, Giri N, Goldman FD, Kolb EA, Krance R, Kurtzberg J, Leung WH, Srivastava A, Or R, Richman CM, Rosenberg PS, Toledo Codina JS, Shenoy S, Socie G, Tolar J, Williams KM, Eapen M, Savage SA

Biol Blood Marrow Transplant. 2013 Aug;19(8):1238-43

Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.

Park S, Labopin M, Yakoub-Agha I, Delaunay J, Dhedin N, Deconinck E, Michallet M, Robin M, De Revel T, Bernard M, Vey N, Lioure B, Lapusan S, Tabrizi R, Bourhis JH, Huynh A, Beguin Y, Socie G, Dreyfus F, Fenaux P, Mohty M

Eur J Haematol. 2013 May;90(5):355-64

Treatment of adult ALL with central nervous system involvement at diagnosis using autologous and allogeneic transplantation: a study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.

Chantepie SP, Mohty M, Tabrizi R, Robin M, Deconinck E, Buzyn A, Contentin N, Raus N, Lheritier V, Reman O

Bone Marrow Transplant. 2013 May;48(5):684-90

Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies.

Rocha V, Labopin M, Ruggeri A, Podesta M, Gallamini A, Bonifazi F, Sanchez-Guijo FM, Rovira M, Socie G, Baltadakis I, Michallet M, Deconinck E, Bacigalupo A, Mohty M, Gluckman E, Frassoni F

Transplantation. 2013 May 27;95(10):1284-91

A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib.

Martino S, Daguindau E, Ferrand C, Bamoulid J, Hayette S, Nicolini FE, Capellier G, Deconinck E, Larosa F

Leuk Res Rep. 2013 Mar 19;2(1):29-31

Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies.

Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M, Vigouroux S, Bories P, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Legrand F, Deconinck E, Fegueux N, Clement L, Dauriac C, Maillard N, Cornillon J, Ades L, Guillerm G, Schmidt-Tanguy A, Marjanovic Z, Park S, Rubio MT, Marolleau JP, Garnier F, Fenaux I, Yakoub-Agha I

J Clin Oncol. 2012 Dec 20;30(36):4533-40

Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database.

Solal-Celigny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, Luminari S, Pro B, Montoto S, Ferreri AJ, Deconinck E, Milpied N, Gordon LI, Federico M

J Clin Oncol. 2012 Nov 1;30(31):3848-53

A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients wit

Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, Vey N, Haioun C, Colombat P, Rossi JF, Deconinck E, Lazreg F, Bergougnoux L, Delsol G, Attal M

Ann Oncol. 2012 Oct;23(10):2687-95

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.

Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Tilly H, Thieblemont C, Bergougnoux L, Lazreg F, Solal-Celigny P

Ann Oncol. 2012 Sep;23(9):2380-5

Intracytoplasmic detection of TCL1--but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis.

Angelot-Delettre F, Biichle S, Ferrand C, Seilles E, Gaugler B, Harrivel V, Rosenthal-Allieri MA, Deconinck E, Saas P, Garnache-Ottou F

Cytometry A. 2012 Aug;81(8):718-24

Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.

Brion A, Legrand F, Larosa F, Schillinger F, Garnache-Ottou F, Helias P, Fontan J, Heczko M, Delaby P, Daguindau E, Vuillier J, Chauchet A, Deconinck E

Invest New Drugs. 2012 Aug;30(4):1697-702

Systematic donor blood qualification by flow cytometry would have been able to avoid CLL-type MBL transmission after unrelated hematopoietic stem cell transplantation.

Ferrand C, Garnache-Ottou F, Collonge-Rame MA, Larosa F, Blanc M, Behar C, Giannoli C, Garnier F, Tiberghien P, Deconinck E, Rohrlich PS

Eur J Haematol. 2012 Mar;88(3):269-72

Double reduced-intensity allogeneic hematopoietic stem cell transplantation: a retrospective study from the SFGM-TC.

Bay JO, Cabrespine A, Faucher C, Tabrizi R, Bordigoni P, Berceanu A, Coiteux V, Renaud M, Mialou V, Robin M, Kuentz M, Chevallier P, Dhedin N, Huynh A, Garban F, Witz F, Buzyn A, De Revel T, Galambrun C, Deconinck E, Contentin N, Francois S, Gratecos N, Blaise D, Michallet M

Biol Blood Marrow Transplant. 2012 Feb;18(2):250-6

CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.

Solly F, Angelot F, Garand R, Ferrand C, Seillès E, Schillinger F, Decobecq A, Billot M, Larosa F, Plouvier E, Deconinck E, Legrand F, Saas P, Rohrlich PS, Garnache-Ottou F

Cytometry A. 2012 Jan;81(1):17-24

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.

Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Foussard C, Salles G

Haematologica. 2011 Aug;96(8):1128-35

Successful mobilization and engraftment of PBSCs derived from donor cord blood cells after a previous allogeneic RIC single unrelated cord blood transplantation.

Larosa F, Deconinck E, Helias P, Fontan J, Heczko M, Brion A, Ledu K, Delaby P, Vuiller J, Ferrand C, Saas P, Pouthier F, Dormoy A, Chabod J, Malugani C, Rohrlich PS, Legrand F

Blood. 2011 Jul 14;118(2):476-8.

Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study.

Legrand F, Grenouillet F, Larosa F, Dalle F, Saas P, Millon L, Deconinck E, Rohrlich PS

Bone Marrow Transplant. 2011 Jun;46(6):858-62

Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.

Monjanel H, Deconinck E, Perrodeau E, Gastinne T, Delwail V, Moreau A, Francois S, Berthou C, Gyan E, Milpied N

Biol Blood Marrow Transplant. 2011 Jun;17(6):935-40

Early immune reconstitution and efficient graft vs tumor effect after unrelated partially matched double cord blood transplantation in refractory 8p11 syndrome.

Larosa F, Maddens S, Legrand F, Pouthier F, Ferrand C, Saas P, Hayette S, Chabod J, Tiberghien P, Rohrlich PS, Deconinck E

Bone Marrow Transplant. 2011 Apr;46(4):622-4

Retrospective assessment of beta-D-(1,3)-glucan for presumptive diagnosis of fungal infections.

Bellanger AP, Grenouillet F, Henon T, Skana F, Legrand F, Deconinck E, Millon L

APMIS. 2011 Apr;119(4-5):280-6

Increased risk of non-Hodgkin lymphoma and serum organochlorine concentrations among neighbors of a municipal solid waste incinerator.

Viel JF, Floret N, Deconinck E, Focant JF, De Pauw E, Cahn JY

Environ Int. 2011 Feb;37(2):449-53

Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors.

Marmier-Savet C, Larosa F, Legrand F, Witz B, Michallet M, Ranta D, Louvat P, Puyraveau M, Raus N, Tavernier M, Mathieu-Nafissi S, Hequet O, Pouthier F, Deconinck E, Tiberghien P, Robinet E

Transfusion. 2010 Dec;50(12):2676-85

Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors.

Nerich V, Limat S, Demarchi M, Borg C, Rohrlich PS, Deconinck E, Westeel V, Villanueva C, Woronoff-Lemsi MC, Pivot X

Int J Med Inform. 2010 Oct;79(10):699-706.

Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.

Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R

Br J Haematol. 2010 Oct;151(2):159-66

Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.

Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, Celigny PS, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy T, Colonna M, Colombat P

Haematologica. 2010 Aug;95(8):1350-7

False-positive Aspergillus real-time PCR assay due to a nutritional supplement in a bone marrow transplant recipient with GVH disease.

Millon L, Grenouillet F, Crouzet J, Larosa F, Loewert S, Bellanger AP, Deconinck E, Legrand F

Med Mycol. 2010 Jun;48(4):661-4.

Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance.

Henry C, Deschamps M, Rohrlich PS, Pallandre JR, Remy-Martin JP, Callanan M, Traverse-Glehen A, GrandClement C, Garnache-Ottou F, Gressin R, Deconinck E, Salles G, Robinet E, Tiberghien P, Borg C, Ferrand C

Blood. 2010 Mar 25;115(12):2420-9

Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma Long-Term Economic Evaluation

Deconinck E, Miadi-Fargier H, Le Pen C, Brice P

Pharmacoeconomics. 2010;28(1):35-46

Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment.

Daguindau E, Lioure B, Buzyn A, Robin M, Faucher C, Kuentz M, Tiberghien P, Deconinck E

Bone Marrow Transplant. 2010 Jan;45(1):177-80

G-CSF-induced aneuploidy does not affect CD34+ cells and does not require cell division.

Marmier-Savet C, Larosa F, Legrand F, Witz B, Michallet M, Ranta D, Louvat P, Puyraveau M, Raus N, Tavernier M, Mathieu-Nafissi S, Hequet O, Pallandre JR, Vitte F, Collonge-Rame MA, Pouthier F, Bresson JL, Deconinck E, Tiberghien P, Robinet E

Blood. 2010 Jan;115(4):910-1

Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen.

Royer B, Larosa F, Legrand F, Gerritsen-van Schieveen P, Berard M, Kantelip JP, Deconinck E

Biol Blood Marrow Transplant. 2009 Sep;15(9):1134-9

Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: a case report.

Piton G, Larosa F, Minello A, Becker MC, Mantion G, Aubin F, Deconinck E, Hillon P, Di Martino V

Liver Transpl. 2009 Jul;15(7):682-5.

Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia.

Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadie M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, Macintyre E, Bene MC, Saas P, Jacob MC

Br J Haematol. 2009 Jun;145(5):624-36

[Banking and indications for cord blood grafts]

Tiberghien P, Chabod J, Deconinck E, Pouthier F

Transfus Clin Biol. 2009 May;16(2):204-8

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.

Kroger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, Devergie A, Ruutu T, Cornish J, Ljungman P, Gratwohl A, Cordonnier C, Beelen D, Deconinck E, Symeonidis A, de Witte T

Haematologica. 2009 Apr;94(4):542-9

Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin's Lymphoma

Fagnoni P, Milpied N, Limat S, Deconinck E, Nerich V, Foussard C, Colombat P, Harousseau JL, Woronoff-Lemsi MC

Pharmacoeconomics. 2009;27(1):55-68

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 year

Gyan E, Foussard C, Bertrand P, Michenet P, Le Gouill S, Berthou C, Maisonneuve H, Delwail V, Gressin R, Quittet P, Vilque JP, Desablens B, Jaubert J, Ramee JF, Arakelyan N, Thyss A, Molucon-Chabrot C, Delepine R, Milpied N, Colombat P, Deconinck E

Blood. 2009 Jan 29;113(5):995-1001

Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.

Saint-Marcoux F, Royer B, Debord J, Larosa F, Legrand F, Deconinck E, Kantelip JP, Marquet P

Clin Pharmacokinet. 2009;48(10):667-75

[Kappa light chain deposition disease, presenting as Sjogren's syndrome, successfully treated by high-dose melphalan and autologous blood stem transplantation]

Foguem C, Kantelip B, Deconinck E, Hafsaoui C, Meaux-Ruault N, Gil H, Magy-Bertrand N, Dupond JL

Rev Med Interne. 2009 Jan;30(1):49-52

Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC.

Chevallier P, Mohty M, Lioure B, Michel G, Contentin N, Deconinck E, Bordigoni P, Vernant JP, Hunault M, Vigouroux S, Blaise D, Tabrizi R, Buzyn A, Socie G, Michallet M, Volteau C, Harousseau JL

J Clin Oncol. 2008 Oct 20;26(30):4940-3

Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response?

Mercier-Letondal P, Deschamps M, Sauce D, Certoux JM, Milpied N, Lioure B, Cahn JY, Deconinck E, Ferrand C, Tiberghien P, Robinet E

Hum Gene Ther. 2008 Sep;19(9):937-50.

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.

Michallet M, Le QH, Mohty M, Prebet T, Nicolini F, Boiron JM, Esperou H, Attal M, Milpied N, Lioure B, Bordigoni P, Yakoub-Agha I, Bourhis JH, Rio B, Deconinck E, Renaud M, Chir Z, Blaise D

Exp Hematol. 2008 May;36(5):535-44

Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft.

Deschamps M, Mercier-Lethondal P, Certoux JM, Henry C, Lioure B, Pagneux C, Cahn JY, Deconinck E, Robinet E, Tiberghien P, Ferrand C

Blood. 2007 Dec 1;110(12):3842-52

Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product.

Calmels B, Lemarie C, Esterni B, Malugani C, Charbonnier A, Coso D, de Colella JM, Deconinck E, Caillot D, Viret F, Ladaique P, Lapierre V, Chabannon C

Transfusion. 2007 Jul;47(7):1268-75.

Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)

Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, Blaise D, Tabrizi R, Garban F, Cassuto JP, Chevalier P, Facon T, Ifrah N, Renaud M, Tilly H, Vernant JP, Kuentz M, Bourhis JH, Bordigoni P, Deconinck E, Lioure B, Socie G, Milpied N

Haematologica. 2007 May;92(5):627-34.

Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

Ades L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P

J Clin Oncol. 2006 Dec 20;24(36):5703-10

Quantitative measurement of Stachybotrys chartarum using real-time PCR in indoor building, agricultural and hospital environments.

Millon L, Reboux G, Bellanger P, Roussel S, Sornin S, Martin C, Deconinck E, Dalphin JC, Piarroux R

J Mycol Med. 2006 Dec;16(4):183-8.

[Cost of hospital-based management of acute myeloid leukemia: from analytical to procedure-based tarification].

Fagnoni P, Limat S, Hintzy-Fein E, Martin F, Deconinck E, Cahn JY, Arveux P, Dussaucy A, Woronoff-Lemsi MC

Bull Cancer. 2006 Aug 1;93(8):813-9.

Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

Ducastelle S, Ades L, Gardin C, Dombret H, Prebet T, Deconinck E, Rio B, Thomas X, Debotton S, Guerci A, Gratecos N, Stamatoullas A, Fegueux N, Dreyfus F, Fenaux P, Wattel E

Haematologica. 2006 Mar;91(3):373-6.

[Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone].

Nollet S, Berger E, Deconinck E, Baldauf E, Rumbach L

Rev Neurol (Paris). 2006 Feb;162(2):195-9.

Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic((R))) resolves gastrointestinal disorders in a patient with severe idiopathic aplastic anaemia.

Rohrlich PS, Deconinck E, Cahn JY, Plouvier E

Drugs. 2006;66 Suppl. 2:33-5.

Intensive therapy before or during the conditioning regimen of allogeneic marrow transplantation in adult acute lymphoblastic leukemia patients: we must choose to reduce Toxicity--a Groupe Ouest-Est d'Etude des Leucemies et Autres Maladies du Sang study.

Deconinck E, Hunault M, Milpied N, Bernard M, Renaud M, Desablens B, Delain M, Witz F, Lioure B, Pignon B, Guyotat D, Berthou C, Jouet JP, Casassus P, Ifrah N, Boiron JM

Biol Blood Marrow Transplant. 2005 Jun;11(6):448-54.

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P, Escoffre-Barbe M, Maisonneuve H, Delwail V, Gressin R, Legouffe E, Vilque JP, Desablens B, Jaubert J, Ramee JF, Jenabian A, Thyss A, Le Pourhiet-Le Mevel A, Travade P, Delepine R, Colombat P

Blood. 2005 May 15;105(10):3817-23

Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation.

Larosa F, Marmier C, Robinet E, Ferrand C, Saas P, Deconinck E, Bulabois CE, Rohrlich PS, Ledu K, Helias P, Tiberghien P, Cahn JY

Bone Marrow Transplant. 2005 May;35(9):859-68.

Cytomegalovirus infection and chronic graft-versus-host disease are significant predictors of renal failure after allogeneic hematopoietic stem cell transplantation.

Deconinck E, Kribs M, Rebibou JM, Bulabois CE, Ducloux D, Cahn JY

Haematologica. 2005 Apr;90(4):569-70.

c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome.

Valnet-Rabier MB, Challier B, Thiebault S, Angonin R, Margueritte G, Mougin C, Kantelip B, Deconinck E, Cahn JY, Fest T

Br J Haematol. 2005 Mar;128(6):767-73.

Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of

Foussard C, Colombat P, Maisonneuve H, Berthou C, Gressin R, Rousselet MC, Rachieru P, Pignon B, Mahe B, Ghandour C, Desablens B, Casassus P, Lamy T, Delwail V, Deconinck E

Ann Oncol. 2005 Mar;16(3):466-72

Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells.

Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E, Jacob MC, Salaun V, Arock M, Drenou B, Schillinger F, Seilles E, Tiberghien P, Bensa JC, Plumas J, Saas P

Blood. 2005 Feb 1;105(3):1256-64

Cost Effectiveness of Cardioprotective Strategies in Patients with Aggressive Non-Hodgkin's Lymphoma.

Limat S, Demesmay K, Fagnoni P, Voillat L, Bernard Y, Deconinck E, Brion A, Arveux P, Cahn JY, Woronoff-Lemsi MC

Clin Drug Investig. 2005;25(11):719-29.

The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study.

Sensebe L, Giraudeau B, Bardiaux L, Deconinck E, Schmidt A, Bidet ML, Leniger C, Hardy E, Babault C, Senecal D

Blood. 2005 Jan 15;105(2):862-4

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL

N Engl J Med. 2004 Mar 25;350(13):1287-95.

A single intravenous infusion of apoptotic cells, an alternative cell-based therapy approach facilitating hematopoietic cell engraftment, did not induce autoimmunity.

Perruche S, Kleinclauss F, Angonin R, Cahn JY, Deconinck E, Reininger L, Boucraut J, Tiberghien P, Saas P

J. Hematother. Stem Cell Res.. 2003 Aug;12(4):451-9

Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma.

Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, Sabbah A, Woronoff-Lemsi MC, Cahn JY

Ann Oncol. 2003 Feb;14(2):277-81.

Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.

Leblond V, Ben-Othman T, Deconinck E, Taksin AL, Harousseau JL, Delgado MA, Delmer A, Maloisel F, Mariette X, Morel P, Clauvel JP, Duboisset P, Entezam S, Hermine O, Merlet M, Yakoub-Agha I, Guibon O, Caspard H, Fort N

J. Clin. Oncol.. 1998 Jun;16(6):2060-4

Fiche personne Projets Publications

Retrouvez aussi

Personnes

Equipes

Plateformes

Unités de recherche, établissements

Projets de recherche

Publications scientifiques